Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares ...

Federal liability protections currently prevent people suing COVID-19 vaccine makers, and instead require them to request ...

Drugmaker Merck announced on Friday that it would soon seek approval from the U.S. Food and Drug Administration for a pill the company claims cuts the risk of hospitalization or death from Covid ...

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares ...

During the pandemic, money flooded into drugmakers’ shares but recently more investors are shifting into Big Tech ...

Merck & Co.’s COVID-19 pill is giving rise to new mutations of the virus in some patients, according to a study that underscores the risk of trying to intentionally alter ...

The first-ever COVID antiviral pill developed by Merck could be available before the end of the year. The drug, molnupiravir, has been shown to reduce the risk of hospitalization and death from ...

Drugmaker Merck has asked U.S. regulators to authorize its promising antiviral pill against COVID-19, setting the stage for a decision within weeks ...

The U.S. government has agreed to purchase 1.4 million more courses of molnupiravir, Merck's experimental COVID-19 antiviral drug, for roughly $1 billion, the drugmaker said Nov. 9.

The Medicines Patent Pool on Jan. 20 said it had signed agreements with 27 generic drugmakers to manufacture molnupiravir — Merck's COVID-19 antiviral — to advance accessibility in 105 ...

Merck & Co.’s COVID-19 pill is giving rise to new mutations of the virus in some patients, according to a study that underscores the risk of trying to intentionally alter ...

Federal health regulators say an experimental COVID-19 pill from Merck is effective against the virus, but they will seek input from outside experts on risks of birth defects and other potential pr… ...